Crinetics Pharmaceuticals CRNX Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's net unrealized gains (losses) on securities still held?
- Crinetics Pharmaceuticals (CRNX) reported net unrealized gains (losses) on securities still held of -$3.15M in Q1 2026.
- How has Crinetics Pharmaceuticals's net unrealized gains (losses) on securities still held changed year-over-year?
- Crinetics Pharmaceuticals's net unrealized gains (losses) on securities still held decreased by 404.6% year-over-year, from $1.03M to -$3.15M.
- What is the long-term trend for Crinetics Pharmaceuticals's net unrealized gains (losses) on securities still held?
- Over 2 years (2021 to 2024), Crinetics Pharmaceuticals's net unrealized gains (losses) on securities still held has grown at a -81.5% compound annual growth rate (CAGR), from -$407K to -$14K.
- What does net unrealized gains (losses) on securities still held mean?
- This represents the change in the fair value of investment securities held by the company that have not yet been sold. It captures fluctuations in the market value of the company's treasury or investment portfolio, which are recognized outside of the traditional income statement. This metric is useful for understanding the impact of market volatility on the company's total financial position.